Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Toripalimab in Advanced Melanoma
NCT05478473Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tucidinostat in melanoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05478473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478473.